Gri bio presents positive preclinical data demonstrating gri-0621's ability to inhibit invariant natural killer t (inkt) cell activity and reduce important inflammatory and fibrotic drivers in idiopathic pulmonary fibrosis (ipf)

Data suggest that nkt cells are activated in airways in idiopathic pulmonary fibrosis (ipf) patients and inhibition of inkt cell activity can treat bleomycin-induced pulmonary fibrosis

GRI Ratings Summary

GRI Quant Ranking